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The employment of the immune system to treat malignant disease represents an active area of biomedical research. The speciﬁcity
of the immune response and potential for establishing long-term tumor immunity compels researchers to continue investigations
into immunotherapeutic approaches for cancer. A number of immunotherapeutic strategies have arisen for the treatment of
malignant disease, including various vaccination schemes, cytokine therapy, adoptive cellular therapy, and monoclonal antibody
therapy. This paper describes each of these strategies and discusses some of the associated successes and limitations. Emphasis is
placed on the integration of techniques to promote optimal scenarios for eliminating cancer.
1.Introduction
As cancer progresses toward the leading cause of death
in the Unites States, physicians and biomedical scientists
continue to explore novel therapeutic strategies outside
the current standard of treatment. Despite the successes
of surgery, radiation, chemotherapy, and a combination
thereof in limiting the progression of malignant disease,
these treatment methods often fail to elicit complete tumor
remission and are associated with some debilitating side
eﬀects. In recent years, much attention has been paid to
immunotherapy, which attempts to direct the protective
capacity of the immune system toward eliminating malig-
nancies. Harnessing the immune system to treat malignant
disease is a powerful tool, not only due to the speciﬁcity
of the immune response, but also due to the potential for
establishing long-lasting tumor immunity via the capacity
to exhibit memory. The ability of the immune system to
destroy tumorigenic cells was ﬁrst proposed by Macfarlane
Burnet in the 1950s [1]. Some years later, Burnet coined
the term “immune surveillance” to describe the function of
the immune system in eliminating transformed cells both
before and after tumor formation [2]. A seminal study
conducted by Shankaran and colleagues in 2001 conﬁrmed
the importance of certain immune components in limiting
the formation of tumors in experimental animals. In this
study, immunocompromised mice were found to be signif-
icantly more susceptible to spontaneous and carcinogen-
induced primary tumor development than immunocom-
petent mice [3]. The critical role of the immune system
in minimizing malignancies engenders profound sequelae
in the human situation as well. Certain immunodeﬁciency
disorders, including AIDS, are strongly associated with an
increased risk of cancer [4]. Additionally, the formation of
tumors in immunosuppressed organ transplant patients and
among individuals receiving stem-cell transplants has been
well documented and represents a major obstacle to the
long-term success of these procedures [5]. Collectively, such
ﬁndings provide an impetus for continual investigation of
the therapeutic potential of antitumor immune responses.
Immunotherapeutic strategies can be categorized broad-
ly into two groups: active immunotherapy and passive im-
munotherapy. Establishing active immunity against tumors
is a promising but inherently diﬃcult task, and necessitates2 Clinical and Developmental Immunology
a keen understanding of the multiple immunosuppressive
mechanisms that the tumor microenvironment may exploit.
According to Waldmann, maximizing the eﬃcacy of active
immunotherapy will require a thorough investigation of
the appropriate target antigens; the optimal interactions
between lymphocytes, antigen-presenting cells (APC), and
antigens; and the obstruction of negative immune regulation
[6]. Although this immunotherapeutic strategy holds the
potential for establishing long-lasting tumor immunity,
the dissolution of immune tolerance to prospective cancer
antigens remains a challenging and controversial process.
The possibility of eliciting rampant autoimmunity in the
wake of tumor reactive lymphocytes remains a key concern
in the ultimate utility of active immunotherapy, particularly
when this therapy is used in combination with other
immunostimula- tory techniques [7, 8].
Passive immunotherapy using clonally expanded tumor-
speciﬁc T cells represents a diﬀerent approach to manip-
ulating components of the host’s immune system to tar-
get cancer. Unlike active approaches, tumor-speciﬁc lym-
phocytes are expanded ex vivo, allowing for more direct
manipulations of the prospective immune eﬀectors. As
with active immunotherapy, however, the possible long-
term eﬀects of harboring self-reactive lymphocytes warrants
further assessment. Additionally, passive immunotherapy
using monoclonal antibodies (MAbs) and immunoglobu-
lin (Ig)-fusion proteins is a rapidly emerging technology
t h a th o l d sg r e a tp o t e n t i a lf o re ﬀectively treating malignant
disease. The increasing incidence of MAb therapy in the
treatment of cancer and other diseases ﬁrmly establishes
the legitimacy of such molecules as eﬀectual and speciﬁc
anticancer agents [9]. A total of nine MAbs and modiﬁed
Ig molecules have been approved by the FDA for use in
cancer patients, and many more are in the process of clinical
trials. Despite the enthusiasm for this type of therapy, several
key challenges still remain for optimizing the eﬃcacy of
these artiﬁcial immune eﬀe c t o r s .S u c hc h a l l e n g e si n c l u d e
minimizing the induction of host-neutralizing antibody
responses and curtailing the residual cytotoxicity of some Ig-
fusion molecules. Additionally, both vaccination and MAb
approaches to tumor immunotherapy may encourage the
generation of tumor cells that evade immune recognition. In
accordancewiththeprocessof“immunoediting,”tumorcells
that bear antigenic targets for vaccination or MAb therapy
are subject to destruction; however, tumors may compensate
by expanding populations of antigenically undetectable
tumor cells [10, 11]. These “immune escape variants” arise
due to selective pressures imparted on the tumor microen-
vironment by antigen-speciﬁc immunotherapies, and subsist
via the strategic masking of antigens that are recognized by
the antitumor immune response.
2. Vaccination As an Immunotherapeutic Tool
2.1. Identiﬁcation of Appropriate Tumor Antigens. Given
the historic success of active immunization in protect-
ing against infectious microbial diseases, many researchers
are attempting to apply vaccination approaches to cancer
immunotherapy. Indeed, several prophylactic vaccines have
been generated against viral infectious agents that are also
causative for certain human cancers. FDA-approved vaccines
against hepatitis B virus (HBV) and human papilloma
virus (HPV) are associated with protection against HBV-
induced liver cancer and HPV induced cervical carcinomas,
respectively. This clearly demonstrates that vaccines can
be produced to prevent human malignancies. There are
several vaccine modalities currently under investigation,
including protein/peptide vaccines, ex-vivo loaded dendritic
cells (DCs), DNA vaccines, and recombinant viral/bacterial
vectors expressing particular tumor antigens. Additionally,
prime-boost vaccine strategies seek to optimize the immune
response by combining two or more of these modalities
into a single treatment regimen. Common prime-boost
strategies include primary immunization with plasmid DNA
and subsequent immunizations with recombinant protein or
viral vectors, although considerable variations on this theme
abound within the literature [12].
The ultimate intention of immunization is induction of
a tumor-speciﬁc immune response, thus the identiﬁcation of
appropriate tumor antigens remains a key concern for each
of these vaccine strategies. Among the various categories of
candidate antigens, tumor-speciﬁc antigens represent ideal
targets, as these molecules are expressed exclusively on
tumor cells. Examples of tumor-speciﬁc antigens include
the products of mutated oncogenes and altered tumor
suppressor proteins. One such tumor suppressor protein is
p53, which plays a critical role in regulation of the cell cycle
and is a target of some oncogenic viral proteins, including
Tax from human T-cell lymphotropic virus-1 (HTLV-1) [13]
and large T antigen (Tag) from simian virus 40 (SV40) [14].
Despite numerous reports of detectable humoral responses
against p53 in cancer patients, the protection aﬀorded by
such responses appears to be minimal [15]. Additionally, the
limited propensity for oncogenic mutants of normal cellular
genes to promote the generation of protective cytotoxic T
lymphocyte (CTL) responses presents a major obstacle to the
exploitation of these antigens [16]. Within the last decade,
several tumor-speciﬁc self-antigens that are recognized by
CTLs have been identiﬁed (including CDK-4, β-catenin, and
Caspase-8),andshowpotentialforincorporationintocancer
vaccines [17].
In addition to tumor-speciﬁc self-antigens, viral onco-
proteins represent a unique class of tumor antigen that,
during the course of viral infection, may be expressed
primarily on transformed cells and infected cells harboring
an increased neoplastic potential. A study performed by
Duraiswamy and colleagues in 2003 provided convincing
evidence of the ability for a polyepitope vaccine directed
against the latent membrane protein 1 (LMP1) of Epstein-
Barr virus (EBV) to provide immunity against aggressive
tumors expressing LMP1 in mice [18]. Importantly, the
tumor immunity evoked in this model was observable
both in a prophylactic setting and in a therapeutic vaccine
scenario. Such ﬁndings continue to compel researchers to
investigatevaccinationschemesthattargetviraloncoproteins
as tumor-speciﬁc antigens. Indeed, the eﬃcacy of both SV40
Tag recombinant protein and SV40 Tag DNA vaccines inClinical and Developmental Immunology 3
protecting mice against Tag expressing tumors has been
well documented by our laboratory [19]. While only a few
viruses have been directly implicated in the generation of
tumors in humans (namely HTLV, EBV, and HPV), the
pathology associated with certain other viruses, including
human immunodeﬁciency virus (HIV), HBV, and hepatitis
C virus (HCV), may promote the development of tumors in
some individuals. Certain viruses may also act synergistically
to provoke tumorigenesis; for example, coinfection with
Kaposi’s sarcoma-associated herpesvirus and HIV often
resultsin the formationof disseminated blood vesseltumors.
In addition to viral pathogens, gastric inﬂammation induced
by the bacterium Helicobacter pylori has been suggested to
encourage the growth of local tumors. Accordingly, vaccines
that eliminate these oncogenic and prooncogenic microbes
may provide protection against malignant disease prior to
the formation of tumor foci.
Unfortunately, many types of cancer do not express
universallyrecognizedantigensthatareassociatedexclusively
withtumorcells.Investigatorsmustthereforeexplore theuse
of other antigens that are expressed diﬀerentially on normal
and cancerous cells. Various categories of tumor associated
antigens (TAAs) have been described, including overex-
pressed self-antigens, diﬀerentiation antigens, and antigens
from immune privileged sites (cancer/testes antigens) [17].
The ﬁrst TAA to be identiﬁed was MAGE-1, which is an
antigen expressed in tumor cells and germ cells and is
prone to recognition by CTLs [20]. The absence of MAGE
expression in most normal adult tissues (including liver,
muscle, skin, lung, brain, and kidney), and the relative
abundance of this antigen in tumors and germline tissues
(e.g., testis, placenta, ovary), qualiﬁes MAGE as a classic
cancer/testes(CT)antigen.Moreover,vaccinesthattargetCT
antigens are unlikely to cause collateral tissue destruction,
as normal adult cells are not transcriptionally active for CT
antigens and germ cells lack the necessary machinery for
antigen presentation to the immune system. Other major
TAA categories include diﬀerentiation antigens, of which the
melanocyte proteins tyrosine and MART are examples, and
overexpressed self-antigens, of which the common breast
cancer antigen HER-2/neu (ErbB2) is an example. These
antigens are thought to be expressed by such a small group
of cells and/or in such limited quantities, that the immune
system fails to induce tolerance to these self proteins. Several
prospective self-antigens have thus been identiﬁed for use
in cancer immunotherapy [21], with some of the more
common antigens listed in Table 1.
2.2. Vaccination Strategies. Although protein/peptide vacci-
nation with puriﬁed antigen plus adjuvant has long served
as an eﬀective vaccine strategy in the prevention of microbial
disease, recent advances in the ﬁeld of vaccine development
may favor the use of DNA-based or APC-based vaccines
in the treatment of malignant disease. Despite numerous
studies that have demonstrated the antitumor potential of
conventional recombinant protein vaccination, this vaccine
modalitymaycurtailantigenpresentationthroughthemajor
histocompatibility complex (MHC) class I pathway and elicit
a predominantly humoral immune response [22]. Since
CTLs are commonly thought to comprise the major eﬀector
cell type in tumor immunity, vaccination methods that
enhance cell mediated immune responses may prove optimal
for use in cancer immunotherapy.
In the early 1990s, Wolﬀ and colleagues reported that
transgene expression in mice could be accomplished upon
direct injection of naked plasmid DNA into mammalian
muscle tissue [23]. Subsequently, Ulmer and colleagues used
another murine model to demonstrate the utility of DNA
vaccines as a preventative against heterologous inﬂuenza
virus infection [24]. Translational studies targeting HIV
and malarial antigens commenced in the late 1990s, and
soon established the safety of this vaccination scenario in
humans [25–27]. Within the last decade, experimental DNA
vaccination in dogs has demonstrated the eﬃcacy of this
vaccine modality in prolonging survival time within the
context of aggressive malignant disease. In one important
study, dogs suﬀering from canine malignant melanoma were
immunized therapeutically with plasmid DNA encoding
human tyrosinase, which is approximately 91% identical to
canine tyrosine [28]. The median survival time of dogs in
this study was 389 days; substantially higher than the <2-3
month survival time observed in historical, stage-matched
controls. Positive clinical outcomes appeared to correlate
withtheinductionofantibodyresponsestocaninetyrosinase
insomeanimals,althoughapotentialroleforTcellmediated
immunity in this system is still under assessment [29].
The ever-growing compendium of literature involving
DNA vaccines reveals a number of key advantages for this
emerging vaccine modality. In contrast to protein/peptide
vaccines, DNA vaccines have adequately demonstrated the
capacity to mobilize both the cell mediated and humoral
arms of the immune system in animal models [8, 22,
30]. In addition, the production of plasmid DNA is less
complicated than that for protein, providing a crucial
economic incentive for the use of this vaccine modality.
The biochemical properties of DNA also permit extensive
handling at room temperature, diminishing the need for
maintenanceofastringentcoldchainduringthedistribution
process [31]. Perhaps the most attractive feature of DNA
vaccines is the option for convenient manipulation of the
encoded immunogen’s nucleotide sequence. This attribute
permitstheimmediategenerationofantigen-cytokinefusion
molecules and other immunostimulatory complexes that
might otherwise be challenging to construct. In the late
1990s, Song and colleagues used a murine model to survey
the helper T cell (Th1) versus Th2 proclivity of various oval-
bumincytokineDNAconstructs,andprovidedevidencethat
signiﬁcant skewing of antigen speciﬁc immune responses
can occur with the use of antigen-cytokine fusion molecules
[32]. Additionally, multiple antigenic targets or multiple
independent cytokines can be incorporated into a single
DNA vector. As with the aforementioned fusion molecules,
studies conducted in mice have indicated that the nature of
the resultant immune response is highly dependent on the
immunostimulatorypenchantofthecytokinesutilizedinthe
vaccine [33]. A ﬁnal potential advantage of DNA vaccination
is that transgene expression is thought to occur over4 Clinical and Developmental Immunology
Table 1: Examples of common tumor antigens.
Category Antigen Associated cancer types
Tumor-speciﬁc - viral
HPV: L1, E6, E7 Cervical carcinoma
HBV: HBsAg Hepatocellular carcinoma
SV40: Tag Malignant pleural mesothelioma
Tumor-speciﬁc - self
CDK-4 Melanoma
β-catenin Melanoma
Caspase-8 Head/neck
CT antigen MAGE-A1 Melanoma, myeloma, bladder, breast, prostate, lung, head/neck,
esophageal, sarcoma
NY-ESO-1 Melanoma, myeloma, bladder, breast, prostate, lung, head/neck,
esophageal, sarcoma
Overexpression
MUC1 Breast, ovarian
MUC13/CA-125 Ovarian
HER-2/neu Breast, melanoma, ovarian, gastric, pancreatic
Mesothelin Malignant pleural mesothelioma, ovarian, pancreatic
PSMA Prostate
TPD52 Prostate, breast, ovarian
Diﬀerentiation
CEA Colon
Gp100 Melanoma
MART-1/Melan-A Melanoma
Tyrosinase Melanoma
PSA Prostate
PAP Prostate
Abbreviations: HPV, human papilloma virus; HBV, hepatitis B virus; SV40, simian virus 40; L, late gene; E, early gene; HBsAg, hepatitis B surface antigen;
Tag, large tumor antigen; CDK, cyclin-dependent kinase; CT, cancer/testis; MAGE, melanoma-associated antigen; NY-ESO, New York esophageal squamous
cell carcinoma; MUC, mucin; CA, cancer antigen; HER/neu, human epidermal receptor/neurological; PSMA, prostate-speciﬁc membrane antigen; TP, tumor
protein; CEA, carcinoembryonic antigen; Gp, glycoprotein; MART/Melan-A, melanoma antigen recognized by T cells/melanoma antigen-A; PSA, prostate
speciﬁc antigen; PAP, prostatic acid phosphatase.
an extended period of time, perhaps obviating the potential
need for an abundance of repetitive booster vaccinations.
Moreover, the protective potential of DNA vaccination in
animals has been substantiated by reports of DNA constructs
mediating long-term tumor immunity, particularly when
utilized in a prime-boost scenario or in combination with
immunomodulators [34, 35].
A major challenge facing DNA vaccines, however, is
the elicitation of a robust immune response in the human
clinical setting. Translational applications of DNA vaccines
have consistently suﬀered from low immunogenicity; con-
sequently, several unique prime-boost strategies have been
developed to amplify the immune response. A multitude of
distinct delivery methods exist for DNA vaccines (including
intramuscularinjection,biolisticgenegundelivery,modiﬁed
viral vectors, etc.), allowing for the creation of a large reper-
toire of heterologous prime-boost scenarios. As mentioned
previously, heterologous prime-boost scenarios generally
focusontheincorporationofdistinctvaccinemodalitiesinto
a single treatment regimen; however, another application of
this technique incorporates a single vaccine modality with
multiple distinct delivery methods into a single treatment
regimen. One particularly successful embodiment of this
strategy in murine models involves priming of the immune
system with an intramuscular or intradermal injection of
plasmid DNA, followed by electroporation of the homolo-
gous DNA in booster immunizations [36, 37]. In addition,
the ability of CD4+ helper T cells to enhance CTL activity
has prompted investigations into prime-boost scenarios that
utilize diﬀerent DNA constructs aimed at engaging distinct
presentation pathways [38]. In the human clinical situation,
Todorova and colleagues showed that speciﬁc antibody
could be induced by vaccinating with alternate injections
of a prostate speciﬁc membrane antigen (PSMA)-expressing
adenoviral vector and plasmid DNA encoding PSMA and
CD86 in a majority of participants [39]. As indicated
previously, cytokines and other immunostimulators can
be incorporated directly into the DNA vector to improve
immunogenicity. Experience with animal models suggests
that prudent selection of these companion molecules may
allow researchers to promote induction of a predominantly
cell mediated or humoral immune response to the encoded
tumor antigen [32, 33].
APC-based vaccines represent another popular vaccine
moiety in cancer research. With this approach, DCs are
harvested from the patient, pulsed with tumor antigens
or transfected with genes encoding these antigens, and
readministratedtothepatient.AswithDNAvaccination,this
vaccine strategy has the potential to augment presentation
through the MHC-class I pathway and subsequently driveClinical and Developmental Immunology 5
the expansion of tumor-speciﬁc CTLs. In translational
studies with melanoma patients, DC vaccines have demon-
strated a keen ability to elicit detectable immune responses;
however, such responses often fail to elicit substantial clinical
responses [40]. As it is often diﬃcult to discern the relative
contributions of DCs and eﬀector T cells in these situations,
a thorough investigation of the in vivo interactions between
these immune cell populations may be required before a
complete understanding of DC function in tumor immunity
can be elucidated [40].
One aspirant application of DC-based immunotherapy
includes the recently reported Sipuleucel-T immunotherapy
(Provenge) developed by Dendreon
TM. With this strategy,
peripheral blood mononuclear cells, including DCs, are
harvested from the patient and activated in vitro with
prostatic acid phosphatase, a diﬀerentiation antigen, linked
to granulocyte-macrophage colony-stimulating factor (GM-
CSF). In a clinical trial with 225 patients experienc-
ing advanced metastatic androgen independent prostate
cancer, Sipuleucel-T immunotherapy was able to extend
survival by ∼4 months [41]. In April 2010, Sipuleucel-T
immunotherapy was approved by the FDA for the treatment
of asymptomatic or minimally symptomatic metastatic,
castrate-resistant prostate cancer. This autologous cellular
immunotherapy represents the ﬁrst therapeutic cancer vac-
cine to acquire FDA approval, and provides encouragement
for the continued development of similar vaccine strategies.
In the protein/peptide pulsed DC scenario, vaccine
eﬃcacy may be largely dependent on the DCs’ ability
to shuttle exogenous antigen through the MHC class I
pathway, enabling cross priming of an array of TAAs to
CD8+ CTLs (Figure 1). Interestingly, recent reports indicate
that the eﬃciency of cross presentation is at least partially
dependent on the length of the antigenic peptides. In a
study performed by Faure and colleagues, shorter peptides
were more eﬃciently presented to CD8+ T cells after
incubation with DCs; however, after an extended chase
period in the absence of peptide, longer peptides were
more eﬃciently presented [43]. The results from this study
indicate that peptide size is an important consideration
in any DC-based elicitation of long-term tumor immu-
nity. In the genetically modiﬁed DC scenario, presentation
through the MHC class I pathway can be accomplished
directly by processing of endogenous antigen within the
DC. Interestingly, bacterial plasmids commonly utilized as
DNA backbones may have self-adjuvanting capabilities, as
unmethylatedCpGregionshavebeenshowntobindToll-like
receptor 9 and stimulate innate immunity [44, 45]. In one
relevantsetting,Yangandcolleaguesusedatransgenicmouse
model to demonstrate that ex vivo stimulation of DCs with
CpG-containing oligodeoxynucleotides plus antigen could
break CD4+ regulatory T cell (Treg)-mediated tolerance of
CD8+ T cells to tumors [46]. In numerous animal models,
immunogenic enhancement of cell-based vaccines has been
accomplished by using novel combinatorial techniques,
such as ex vivo transfection of DCs with lentiviral vectors
that harbor antigen-encoding DNA [16, 47–49]. Aside
from conventional tumor-focused approaches, experimental
APC-based vaccines aimed at treating chronic viral infec-
tions, such as HCV infection [50], may indirectly reduce the
onset of virally induced cancers.
3. Cytokine-BasedImmunotherapy
Inadditiontoactiveimmunization,cytokine-basedtherapies
embody a direct attempt to stimulate the patient’s own
immune system to reject cancer. A number of strategies exist
for introducing cytokines into cancer patients, including
the incorporation of cytokine genes into DNA vaccines
and the systemic administration of immunostimulatory
molecules. If cytokines are incorporated into a DNA vec-
tor, direct transfection of autologous tumor cells denotes
a possible treatment option. This might allow for the
localization of cytokines to the tumor site, promoting
the expansion of neighboring immune cells and possibly
abrogating the need for additional treatment with anti-
genic peptides. Indeed, antitumor responses directed against
genetically modiﬁed tumor cells have been documented
in a number of murine models exploring a number of
prospective immunotherapeutic cytokines. These models
have generally focused on tumor immunity mediated by
cytokines that promote diﬀerentiation of the Th1 subset
of CD4+ T cells, including IL-12 [51], IL-18 [51], IL-15
[52], IL-21 [53], IL-23 [54, 55], and IL-27 [56], among
others. Before this approach can be utilized to its max-
imum potential, however, a precise understanding of the
resultant tumor microenvironment and of the recruited
immune cells is necessary. For example, the incorporation
of certain proinﬂammatory cytokines (e.g., IL-1, IL-6)
into the immunosuppressive tumor microenvironment may
encourage the generation of somewhat enigmatic T cell
populations, including Th17 cells. While there is compelling
evidence that Th17 cells may beget tumor immunity by
recruiting tumor reactive CTLs into the tumor site [57],
it is important to consider that this cell population was
initially described within the context of autoimmunity [58–
61]. Further assessment of the pathologic versus protective
functions of such cell subsets should be performed prior
to their intentional or unintentional employment in tumor
immunity.
At the opposite end of the cytokine-based treatment
spectrum is the systemic administration of cytokines. Uti-
lization of cytokines in this manner presumably stimulates
the proliferation of certain immune cells in a non-speciﬁc
manner, expanding immune cell populations that may
include protective tumor-inﬁltrating lymphocytes (TILs).
The eﬃcacy of intravenously introduced IL-2 in patients
with metastatic melanoma or renal cell cancer has been
documented in a number of studies [62, 63], but discern-
ing the appropriate dosage and treatment schedule with
immunostimulatory cytokines remains a time-consuming
and trying process. Alternatively, murine models indicate
that the use of cytokine therapy in combination with other
treatment modalities, including CpG-containing peptide
vaccines [64], may obviate the need for high-dose adminis-
tration of cytokines and lower the incidence of treatment-
associated sepsis.6 Clinical and Developmental Immunology
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Figure 1: General mechanism of tumor antigen cross-priming to CD8+ T cells. In the process of cross-priming, exogenous tumor antigen
(which may be released from tumor cells via apoptosis, necrosis, or immune-mediated damage) is endocystosed by the DC. Antigen then
escapes from the endosome and is processed and loaded onto MHC class I alongside cytosolic antigens. Peptide-loaded MHC class I
molecules are ultimately transported to the cell surface, where they may encounter and activate CD8+ T cells through interactions with
the T cell receptor [42].
As mentioned previously, IL-2 is a cytokine commonly
used in studies of tumor immunotherapy. IL-2 has been
shown to subvert cancer progression in some patients [62,
63]; however, the T cell mediated production of proinﬂam-
matory cytokines in response to this cytokine can result
in severe toxicity and limits its use as a singular treatment
modality. In addition, IL-2 has been implicated in eliminat-
ing self-reactive T cells by a process known as activation-
induced cell death, which may obscure the antitumor eﬀects
of T lymphocytes produced within the tumor microenviron-
ment [65]. Despite these setbacks, intravenously adminis-
tered IL-2 endures as an FDA approved immunotherapeutic
treatment option for patients with metastatic melanoma or
renal cell carcinoma. Another commonly studied cytokine
in cancer immunotherapy is GM-CSF, which acts pre-
dominantly by promoting the recruitment and maturation
of DCs. The antitumor eﬀects of GM-CSF have been
documented in numerous studies, often in conjunction with
vaccinesorotherimmunotherapeuticstrategies.Onenotable
study conducted in 2002 surveyed various immunostim-
ulatory molecules for their ability to enhance antitumor
immune responses across multiple murine models [66]. In
this study, GM-CSF consistently proved to be the most
potent of the tested products. In addition to IL-2 and GM-
CSF, several other cytokines, including various interleukins,
interferons (IFNs), and tumor necrosis factor, have been
investigated for their immunotherapeutic potential. As is the
case with IL-2, most of these cytokines are limited by some
degree of systemic toxicity. In spite of this, a recent study
performed with an experimental renal carcinoma model
suggests that sub-optimal doses of combined IL-21 and
IFN-αcanmediate antitumor immunity withoutthe appear-
a n c eo fa d v e r s es i d ee ﬀects [67].
4.Adoptive CellularTherapy
Insomecancerpatients,passiveimmunizationwithimmune
eﬀectors may constitute a more practical or desirable
approachtoimmunotherapy thanactiveimmunization. One
such treatment method is adoptive cellular therapy, which
utilizes modiﬁed components of the patient’s own immune
cell repertoire to promote rejection of established tumors.
In adoptive cellular therapy, peripheral blood leukocytes
or TILs are harvested from the patient, expanded in vitro
with antigen or stimulatory cytokines, and injected back
into the patient. The culturing of NK cells in the presence
of IL-2 generates lymphokine-activated killer cells, which,
in conjunction with CTLs, are capable of mounting an
aggressive immune response to tumor cells. In 1994, Rosen-
berg and colleagues demonstrated the utility of adoptive
cellular therapy in metastatic melanoma patients by transfer
of autologous TILs in combination with high-dose IL-2 [68].
The response rate of the 86 patients treated in this clinical
study approached 34%, although responses were generally
characterized by a short duration. A few years later, Yee
and colleagues performed an assessment of adoptive cellular
therapy in metastatic melanoma patients by selecting and
expanding TAA-reactive CTL clones from peripheral blood
mononuclear cells [69]. Although regression of individual
metastases was reported, the results from this study failed to
yield objective responses according to RECIST criteria [70].Clinical and Developmental Immunology 7
Interestingly,lymphodepletionwithchemotherapeuticdrugs
prior to the onset of adoptive cellular therapy has led to
vast improvements in the eﬃcacyof this immunotherapeutic
modality. In a study performed by Dudley and colleagues
in 2005, over 50% of metastatic melanoma patients experi-
enced objective reponses according to RECIST criteria upon
treatment with lymphodepleting chemotherapy followed by
adoptive transfer of tumor reactive lymphocytes [71]. The
prevailing logic behind this combinatorial approach is that
endogenous toleragenic host lymphocytes compete with the
transferred cells for homeostatic cytokines, and must be
depletedpriortoadoptivecellulartherapyinordertoachieve
optimum antitumor responses. Additionally, activation and
loading of endogenous DCs may be enhanced by the milieu
of tumor antigens released upon the administration of
chemotherapeutic agents [72].
Aside from the standard expansion protocols for eﬀector
and antigen presenting cells, adoptive cellular therapy allows
for direct ex-vivo manipulation of these immune cell pop-
ulations. Extraction of a general pool of lymphocytes may
complicate the process of identifying and expanding certain
antitumor lymphocytes in vitro, thus some researchers have
explored the introduction of speciﬁc T cell receptors (TCRs)
directly into these cells. This technology can be used to
rapidly generate a band of chimeric T cells reactive towards
a particular antigen; a strategy that may prove particularly
useful for patients with nominal quantities of TILs. Addi-
tionally, the use of novel molecules such as “TCR-like” Fab
fragments may avert problems associated with unintentional
pairing of endogenous and introduced TCR chains [73]. In
any case, the eﬃcacy of genetically modiﬁed lymphocytes
in combating tumor outgrowth has been observed in the
clinical setting [74]. In addition to genetic engineering of
TCRs, the production of modiﬁed antigenic peptides may
beget enhanced T cell induction for use in adoptive cellular
immunotherapy [75]. Despite these exciting and promising
new technologies for adoptive cell transfer, the practicality of
extending this time-consuming and expensive procedure to
the general public remains to be determined.
5. Monoclonal Antibodies As
an Immunotherapeutic Tool
The use of MAbs and antibody conjugates to treat malignant
diseasehasheldtheinterestofthescientiﬁccommunitysince
the time of Ehrlich [76]. Moreover, the FDA’s approval of
nine MAbs for the treatment of cancer has placed a promis-
ing outlook on the expansion of this therapeutic modality in
the near future. Akin to immunotherapeutic vaccines, MAbs
are designed to target speciﬁc antigenic sequences associated
with tumor cells; however, these antigenic targets generally
must reside on the surface of the cell in order for antibody
therapy to be eﬀective. Additionally, MAbs and cancer vac-
cines share the potential for extensive molecular modiﬁca-
tion to improve the eﬀectiveness of immunotherapy. Unlike
cancer vaccines, supplementary molecules fused to MAbs
need not be peptides, as various toxins and radioisotopes
can also be eﬀectively conjugated to the Fc region of the
Ig molecule. Experimental murine models have indicated
that antibody dependent cell-mediated cytoxicity (ADCC)
is an important eﬀector mechanism of antitumor antibodies
[77]; however, additional methods of tumor eradication may
include opsonization followed by phagocytosis and activa-
tion of complement. One potential advantage of MAbs over
cancer vaccines is that the number of circulating immune
eﬀectors in the patient can be raised simply by increasing
the dosage, a feat that is not always easily achievable in
cancer vaccines. At the very least, MAb therapy may serve as
an eﬀectual alternative to cancer immunization, particularly
in situations where the development of autoimmunity is a
concern.
Table 2 provides a list of the MAbs approved for ther-
apeutic use in cancer patients by the FDA. Of the nine
molecules, two represent radioimmunoconjugates (ibritu-
momab tiuxetan and 131I-tositumomab), and one (gem-
tuzumab ozogamicin) represents a cytotoxin-conjugated
antibody. These molecules are unique in that the direct
antitumor eﬀect elicited by the accompanying radioisotope
or cytotoxin trivializes the need for engagement antibody Fc
regions for ADCC or other natural eﬀectormechanisms. The
eﬃcacyofsuchmodiﬁedMAbsoveranextendedtimeperiod
may be limited, however, due to the potent cytotopathic
eﬀects of residual molecules circulating through the body,
and the induction of neutralizing immune responses to the
conjugated toxin and/or non-humanized antibody regions.
Additionally, animal models indicate that antiidiotype
responses to the MAb used for treatment can also potentially
neutralize the eﬀectiveness for targeting the tumor [78].
Many of the MAbs, including trastuzumab and rituximab,
consist of humanized or chimeric Fc regions and, for both of
these therapeutic agents, indications of a role for ADCC have
been reported [79, 80]. While the antigenic targets for most
of the approved MAbs are characteristic tumor cell markers
(including the B cell activation marker CD20, the myeloid
transmembrane receptor CD33, and the lymphocyte surface
antigen CD52), three of these therapeutic agents (cetuximab,
bevacizumab, and panitumumab) target molecules directly
implicated in tumor cell outgrowth. In some cancers,
tumor formation is dependent on aberrant expression of
epidermal growth factor receptor (EGFR), which serves
as an antigenic target for cetuximab and panitumumab.
Similarly, bevacizumab targets vascular endothelial growth
factor (VEGF), which is a secreted factor that promotes
angiogenesis within the immediate vicinity of the tumor.
These latter MAb treatment modalities have a broad based
potential for a variety of cancers and their indicated uses are
being expanded.
In addition to the direct targeting to tumor cells via
MAb therapy, the blockade of negative immunoregulatory
mechanisms may contribute to the arsenal of immunother-
apeutic treatments for cancer. The use of MAbs against
immunosuppressant molecules, such as cytotoxic T lympho-
cyte antigen 4, has been explored and met with positive
results in both human and murine models [81, 82]. Direct
depletion of CD4+ CD25+ Tregs with low doses of an
anti CD25 MAb has also been attempted and shown to
be eﬃcacious in murine models [83]. A reduction in8 Clinical and Developmental Immunology
Table 2: FDA approved monoclonal antibodies for use in cancer therapy.
Antibody Target Developer Approved cancer treatments
Rituximab CD20 IDEC Pharmaceuticals Non-Hodgkin lymphoma
Trastuzumab ErbB2 Genentech/UCLA Breast
Gemtuzumab ozogamicin CD33 Wyeth Acute myeloid leukemia
Alemtuzumab CD52 Genzyme Corporation Chronic lymphocytic leukemia
Ibritumomab tiuxetan CD20 IDEC Pharmaceuticals Non-Hodgkin lymphoma
131I-tositumomab CD20 Corixa Non-Hodgkin lymphoma
Cetuximab EGFR ImClone Systems Colorectal, head/neck
Bevacizumab VEGF Genentech Colorectal
Panitumumab EGFR Amgen Colorectal
Abbreviations: EGFR, epidermal growth factor receptor; VEGF; vascular endothelial growth factor.
Treg numbers may prove pivotal in disrupting tolerance
to antigens within the tumor microenvironment, as this
cell population is suspected to play a signiﬁcant role in
promotingimmunetolerancetoimmunogenicdeterminants
in many cancers [84]. Interestingly, the general population
of Tregs can be broken down into distinct subpopulations,
which may independently eﬀect tolerance to tumor cells
and express diﬀerent markers for targeted depletion [84–86].
Paradoxically, other reports utilizing MAbs against the IL-
2 receptor (CD25) have focused on the application of this
approach as a mediator of generalized immune suppression
[87]. In these scenarios, CD25 expressed on activated CD4+
and CD8+ T cells serves as the intended target for MAb-
mediated depletion, as opposed to CD25 expressed on Tregs.
Such discrepancies illustrate the complexities associated with
immunotherapeutic strategies targeting common molecules
that are expressed on disparate cell subsets.
6. Contraindications for Immune Mechanisms
inProtectingAgainst Tumors
In addition to the role of the immune system in eliminating
tumorigenic cells, it is well appreciated that the immune
system can contribute, under certain circumstances, to the
formation of tumors. Aside from the inherent diﬃculties
in mounting robust immune responses to elements of self,
both the innate and adaptive immune systems can directly
confound mechanisms of tumor prevention and cure [88].
As mentioned previously, Tregs are thought to play an
imperative role in mediating tolerance to some tumors.
Although the mechanisms by which these cells mediate
immune tolerance are still somewhat unclear, they may
involve contact dependent inhibition of activated eﬀector
lymphocytes, as well as secretion of immunosuppressive
cytokines such as IL-10 and transforming growth factor-
β [89]. In experimental murine models of cancer and
autoimmune disease, removal of Tregs has consistently been
shown to enhance immune responses, resulting in inhibition
of tumorigenic growth and exacerbation of autoimmune
disease, respectively [90]. Furthermore, inﬁltrates of Tregs
are commonly observed in sites of chronic viral disease,
where they may function to inhibit immune responses to
microbial pathogens in a capacity similar to that for tumors.
In addition to the various regulatory components of
adaptive immunity that may disrupt immune responses to
tumors,certainaspectsofinnateimmunityappeartodirectly
promote tumorigenesis under some circumstances. Chronic
inﬂammationhaslongbeenregardedasamajorcontributing
factor to the formation of tumors, and is often considered
an important factor in the prognosis associated with certain
cancers [91]. As indicated previously, chronic inﬂammation
induced by microbial pathogens such as H. pylori,H B V ,a n d
HCV often correlates with tumor development in infected
tissues. The constant tissue remodeling and angiogenesis
associated with localized inﬂammation is apt to create a sup-
portive environment for tumor formation and maintenance,
while the actual process of oncogenesis may be accomplished
by the release of DNA-damaging oxygen species and other
toxic molecules from local leukocytes. Importantly, chronic
inﬂammation may be supported by helper T cells and
other components of adaptive immunity, which can activate
r e s i d e n tl e u k o c y t e s ,s u c ha sm a c r o p h a g e s ,a sw e l la ss e c r e t e
proinﬂammatory cytokines. Moreover, the ultimate role of
inﬂammation in preventing versus protecting from tumor
development deserves further assessment, although it is
curious that long-term usage of certain antiinﬂammatory
drugs, such as cyclooxygenase-2 inhibitors, can signiﬁcantly
reduce the risk of cancer [92].
7. Conclusions
The application of immunotherapeutic techniques to treat
cancer is a vital and compelling pursuit of modern medicine.
The increasing incidence of cancer in the western world
demands continued evaluation of such techniques, and
the development of new therapeutic strategies to combat
malignant disease. A multitude of immunotherapeutic tech-
niques, comprising eﬀorts to exploit both active and passive
immunity, are currently under investigation. Within the last
decade, a small but growing body of therapeutic protocols
representingvaccination,cytokinetherapy,andMAbtherapy
have achieved FDA approval for the treatment of malignant
disease. Interestingly, the most impressive clinical data has
probably come from adoptive cellular therapy; however, at
present, this approach has failed to proceed beyond clinical
trials. One technique that may hold considerable promise forClinical and Developmental Immunology 9
the future of cancer immunotherapy is vaccination. Indeed,
the profound achievements of vaccination in controlling
infectious disease have prompted a number of laboratories,
including our own, to devote particular attention to the
application of this approach to treat cancer. Moreover, a
combination of current therapeutic strategies will likely be a
key component in maximizing immune responses to various
cancers, and in providing cancer patients with a comprehen-
siveselectionoftreatmentoptions.Perhapsintheforeseeable
future, prudently crafted immunotherapeutics will overtake
chemotherapy, radiation, and surgery as the dominant and
less toxic strategy for treating malignant disease, and will
provide cancer patients with eﬀective treatment options for
most, if not all, known human malignancies.
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